ProCE Banner Activity

SACI-IO HR+: Phase II Trial of Sacituzumab Govitecan ± Pembrolizumab in HR+/HER2- Metastatic Breast Cancer

Conference Coverage

Primary results from the phase II SACI-IO HR+ trial showed that the addition of pembrolizumab to sacituzumab govitecan did not significantly improve PFS or OS vs sacituzumab govitecan alone in patients with HR+/HER2- metastatic breast cancer, though there was a trend toward improved OS and PFS in the subgroup of patients with PD-L1–positive disease. 

Released: June 04, 2024

Expiration: June 03, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Novartis Pharmaceuticals Corporation.


Daiichi Sankyo, Inc.

Novartis Pharmaceuticals Corporation